LONDON (Reuters) – An experimental drug from GlaxoSmithKline, designed to fight heart disease in a new way, failed to meet its main goal in the first of two big late-stage clinical studies, the company said on Tuesday.
Darapladib did, however, produce greater reductions in serious coronary events in some of the pre-defined secondary endpoints that GSK said required further analysis.
The once-daily pill, which is designed to prevent heart attacks and strokes by fighting clogged arteries in a completely different way from cholesterol-lowering drugs, has been viewed by analysts as a high-risk project.
(Reporting by Ben Hirschler)
- Health
- Pharmaceuticals & Drug Trials
- GlaxoSmithKline
- experimental drug
- heart attacks
Advertisement
You have just read the article News for today's that category by title GlaxoSmithKline heart drug misses goal in major study [ BeritaTerkini ]. You can bookmark this page with a URL http://news-these-days.blogspot.com/2013/11/glaxosmithkline-heart-drug-misses-goal.html. Thank you!
Posted by: Tukiyooo
GlaxoSmithKline heart drug misses goal in major study [ BeritaTerkini ] Updated at :
12:12 AM
Tuesday, November 12, 2013
Post a Comment